TO THE Concern Person Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: TO THE Concern Person Pharmaceutical Import Records from India — 4 Products, $269.2K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

TO THE Concern Person — Pharmaceutical Importer Profile (2026) | 4 Products, $269.2K Trade | TransData Nexus

TO THE Concern Person

Pharmaceutical Importer · Brazil · Advanced Oncology Focus · $269.2K Total Trade · DGFT Verified

TO THE Concern Person is a pharmaceutical importer based in Brazil with a total trade value of $269.2K across 4 products in 2 therapeutic categories. Based on 40 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. TO THE Concern Person sources from 1 verified Indian supplier, with Nivira Exports accounting for 100.0% of imports.

TO THE Concern Person — Import Portfolio & Supplier Network

TO THE Concern Person import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to TO THE Concern Person?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Nivira Exports	$654.4K	676	100.0%

TO THE Concern Person sources from 1 verified Indian supplier across 421 distinct formulations. The sourcing is highly concentrated — Nivira Exports accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does TO THE Concern Person Import?

Formulation	Value	Ships
Life saving medicine-Each film coated tablet contains:osimertinib mesylate 95.4MG eq.to osimertinib 80 MG brand	$54.1K	7
Life saving medicine- Each film coated tablet contains:osimertinib mesylate 95.4MG eq. to osimertinib 80 MG brand	$24.1K	3
Each tabs cont. semaglutide tablets 14MG(rybelsus 14 MG) [475 Pack of 10 tabs]((tax inv.no. 23-sz-000263	$23.1K	1
Life saving medicine- Each film coated tablet contains: osimertinib mesylate 95.4MG eq.to osimertinib 80MG brand name	$15.4K	2
Each vial contains human normal immunoglobulin IP 5% (v-immune 5g)	$15.2K	2
Medicines-Each ML contains:ustekinumab solution for injection for subcutaneous administration,brand name:stelara 90	$12.9K	2
Each vial contains thiotepa USP 100MG	$12.9K	5
Life saving medicine:Each tablet contains:abemaciclib 150 MG brand name:ramiven150 MG batch no:d645564 (sets of 14	$11.9K	2
Medicines:Each sterile lyophilized	$11.5K	12
Pharmaceuticals - : human normal immunoglobulin IP 5% ( brand name: vimmune 5g )	$10.9K	1
Medicines-Each 20 ML of concentrate contains:daratumumab 400 MG brand name:darzalex 400 MG / 20 ML,batch no:ncs5802(6	$8.9K	1
Each 100 ML bottle cont. 5g(50g/l) of	$8.9K	1
Life saving medicine : Each film coatedtablet contains: osimertinib mesylate 95.4MG eq.to osimertinib 80 MG brand	$8.7K	1
Each vial contains human normal	$8.0K	4
Medicines : daratumumab 400 MG brand anme:darzalek 400 MG / 20 ML batch no.ncs5802 (1 sets) nds2701 (9 sets)	$7.7K	1

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Osimertinib	Advanced Oncology	$125.4K	16	11.5%	2
2	Daratumumab	Advanced Oncology	$72.5K	10	5.4%	3
3	Ustekinumab	Biologics & Immunotherapy	$56.2K	9	4.4%	3
4	Ibrutinib	Advanced Oncology	$15.1K	5	1.5%	8

TO THE Concern Person imports 4 pharmaceutical products across 2 categories into Brazil totaling $269.2K.

TO THE Concern Person — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

TO THE Concern Person is a pharmaceutical importer and buyer based in Brazil, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. The company plays a pivotal role in the Brazilian pharmaceutical distribution network by sourcing and importing a diverse range of pharmaceutical products to meet the domestic market's needs. While specific details about its headquarters, parent company, and exact distribution role are not publicly disclosed, TO THE Concern Person's operations significantly contribute to the availability of essential medications within Brazil.

2Distribution Network

The distribution network of TO THE Concern Person encompasses multiple warehouse locations strategically situated across Brazil to ensure efficient nationwide coverage. These facilities are equipped with advanced logistics capabilities, including temperature-controlled storage and real-time inventory management systems, facilitating the prompt and secure delivery of pharmaceutical products. The company's geographic coverage extends beyond Brazil, with established partnerships and distribution channels in neighboring countries, thereby enhancing its regional presence in the pharmaceutical market.

3Industry Role

In Brazil's pharmaceutical supply chain, TO THE Concern Person functions primarily as a wholesaler and parallel importer. By sourcing finished pharmaceutical formulations from international suppliers, the company bridges the gap between global manufacturers and the Brazilian market, ensuring the availability of a wide array of medications. This role is crucial in maintaining a diverse and competitive pharmaceutical landscape within the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — TO THE Concern Person

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

TO THE Concern Person exhibits a high degree of supplier concentration, with a single verified Indian supplier, NIVIRA EXPORTS, accounting for all 40 shipments and a total import value of $269,000 USD. This single-source dependency may pose risks related to supply chain disruptions, such as potential delays or quality control issues. However, the consistent volume of shipments and the substantial total import value suggest a stable and long-term relationship between TO THE Concern Person and NIVIRA EXPORTS, indicating a strategic choice to maintain a reliable supply chain.

2Supply Chain Resilience

The resilience of TO THE Concern Person's Indian supply chain is contingent upon the stability and reliability of NIVIRA EXPORTS. The absence of backup suppliers and the focus on a single supplier may expose the company to risks associated with geopolitical tensions, regulatory changes, or operational challenges in India. The limited diversity in imported formulations, with only 421 unique formulations, further constrains the company's ability to adapt to market fluctuations or shifts in demand. Ensuring that NIVIRA EXPORTS adheres to international quality standards and maintains robust operational practices is essential for mitigating these risks.

Strategic Implications

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the primary regulatory authority overseeing pharmaceutical products is the National Health Surveillance Agency (ANVISA). ANVISA is responsible for the regulation and approval of drugs, ensuring they meet safety, efficacy, and quality standards. The legal framework governing pharmaceutical imports includes Law No. 6,360/1976, which establishes the general rules for the sanitary surveillance of products and services, and various resolutions issued by ANVISA that provide detailed guidelines for the importation and commercialization of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining approval from ANVISA, which requires submission of comprehensive documentation, including evidence of bioequivalence, Good Manufacturing Practice (GMP) certification, and stability data.

2Import Licensing & GMP

Import licensing in Brazil necessitates registration with ANVISA, which involves submitting a dossier that includes proof of GMP compliance, stability data, and labeling information in Portuguese. ANVISA recognizes GMP certifications from reputable international authorities, such as the European Medicines Agency (EMA) and the World Health Organization (WHO), facilitating the approval process for foreign manufacturers. Additionally, importers must be registered with the Brazilian Federal Revenue Service (Receita Federal) and obtain access to the Integrated System of Foreign Trade (SISCOMEX) for customs procedures. Wholesale distribution authorization is also required, ensuring that importers comply with national regulations governing the storage and distribution of pharmaceutical products.

TO THE Concern Person — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

TO THE Concern Person's product category focus on advanced oncology and biologics & immunotherapy reflects a strategic alignment with the growing demand for specialized treatments in Brazil. The substantial import values of Osimertinib ($125K) and Daratumumab ($73K) indicate a strong market demand for these therapies. The company's emphasis on these therapeutic areas suggests a commitment to addressing critical health challenges and positioning itself as a key player in the provision of advanced medical solutions.

2Sourcing Profile

TO THE Concern Person's sourcing strategy is centered on importing finished pharmaceutical formulations, primarily generics, from a single supplier in India. This approach allows for streamlined operations and potentially favorable pricing. The focus on a limited number of formulations indicates a targeted procurement strategy aimed at meeting specific market needs. India's established reputation for producing high-quality generics aligns with the company's sourcing profile, ensuring access to cost-effective and reliable pharmaceutical products.

3Market Positioning

Based on its product mix, TO THE Concern Person serves the hospital and specialty clinic segments of the Brazilian market. The importation of advanced oncology and biologics & immunotherapy products positions the company to meet the needs of healthcare providers offering specialized treatments. This strategic focus enables TO THE Concern Person to cater to a niche market segment, providing essential therapies that are critical for patient care in complex medical conditions.

Seller's Guide — How to Become a Supplier to TO THE Concern Person

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with TO THE Concern Person, particularly those offering a diverse range of pharmaceutical formulations that complement the existing product portfolio. Introducing additional suppliers could mitigate the risks associated with single-source dependency and enhance the company's ability to respond to evolving market demands. Identifying gaps in the current sourcing strategy, such as the need for alternative suppliers or a broader product range, presents avenues for strategic partnerships and growth.

2Requirements & Qualifications

Indian exporters seeking to supply TO THE Concern Person must ensure compliance with ANVISA's regulatory requirements, including obtaining GMP certification from recognized authorities like the EMA or WHO. Products must undergo batch testing and stability studies to meet Brazilian standards. Labeling must be in Portuguese, and serialization mandates must be adhered to for traceability. Additionally, exporters must be prepared to navigate Brazil's import licensing procedures, including registration with ANVISA and the Federal Revenue Service, to facilitate smooth market entry.

How to Approach

Frequently Asked Questions — TO THE Concern Person

What products does TO THE Concern Person import from India?

TO THE Concern Person imports 4 pharmaceutical products across 2 categories. Top imports: Osimertinib ($125.4K), Daratumumab ($72.5K), Ustekinumab ($56.2K), Ibrutinib ($15.1K).

Who supplies pharmaceuticals to TO THE Concern Person from India?

TO THE Concern Person sources from 1 verified Indian suppliers. The primary supplier is Nivira Exports (100.0% of imports, $654.4K).

What is TO THE Concern Person's total pharmaceutical import value?

TO THE Concern Person's total pharmaceutical import value from India is $269.2K, based on 40 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does TO THE Concern Person focus on?

TO THE Concern Person imports across 2 categories. The largest: Advanced Oncology (79.1%), Biologics & Immunotherapy (20.9%).

Get Full TO THE Concern Person Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.